has function has role vaccinated in route immunizes against disease immunizes recipient leukemia Homo sapiens subcutaneous route therapeutic vaccine function peptide vaccine vaccine in clinical trial role peptide vaccine role leukemia cancer vaccine Bcr-Abl (b3a2)-derived peptide vaccine Hayleigh Kahn cancer vaccine Gene name: bcr-abl VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6274 NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61310 NCT: https://clinicaltrials.gov/study/NCT00466726 Jie Zheng A cancer vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b2a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b2a2 fusion protein. The vaccine is made from made from the proteins that cause leukemia cells in CML to behave abnormally. Imatinib mesylate is the standard therapy for CML and blocks the function of this protein. In combination, these may decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease. 6274 25 therapeutic cancer vaccine